NCT01764789

Brief Summary

This pilot clinical trial studies stress reduction in improving quality of life in patients with recurrent gynecologic or breast cancer. Participating in a stress reduction program may help improve quality of life in patients with gynecologic or breast cancer.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
39

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Oct 2010

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2010

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2012

Completed
1 year until next milestone

First Submitted

Initial submission to the registry

January 8, 2013

Completed
2 days until next milestone

First Posted

Study publicly available on registry

January 10, 2013

Completed
Last Updated

October 9, 2015

Status Verified

October 1, 2015

Enrollment Period

1.3 years

First QC Date

January 8, 2013

Last Update Submit

October 8, 2015

Conditions

Keywords

psychological interventionbreast cancergynecologic cancer

Outcome Measures

Primary Outcomes (1)

  • Quality of life(QoL)

    Quality of life as assessed by Short Form (SF)-36

    up to 28 weeks

Secondary Outcomes (7)

  • Mood as assessed by the Profile of Mood States (POMS)

    Up to 28 weeks

  • Depressive symptoms as assessed by the Center for Epidemiological Studies, Depression scale (CES-D)

    Up to 28 weeks

  • Stress as assessed by the Impact of Event Scale (IES)

    Up to 28 weeks

  • Pain as assessed by the Brief Pain Inventory (BPI)

    Up to 28 weeks

  • Fatigue as assessed by the Fatigue Severity Index (FSI)

    Up to 28 weeks

  • +2 more secondary outcomes

Study Arms (1)

Supportive care (psychosocial intervention)

EXPERIMENTAL

Patients participate in a multi-component intervention based on cognitive and behavioral principles comprising MBSR, an intervention to promote hopefulness, and a problem solving approach which navigates around obstacles or generates alternatives when goals become blocked. Additional topics may be covered as indicated by clinical need and patients goals. Biobehavioral components include addressing social and disease-specific quality of life, and pain education. Intensive treatment sessions continue weekly for 16 weeks followed by 2 biweekly and 2 monthly maintenance sessions.

Other: questionnaire administrationProcedure: quality-of-life assessmentProcedure: psychosocial assessment and careBehavioral: behavioral interventionOther: cognitive interventionOther: educational intervention

Interventions

Ancillary studies

Supportive care (psychosocial intervention)

Patients will participate in a quality life assessment.

Also known as: quality of life assessment, Ancillary studies
Supportive care (psychosocial intervention)

Participate in multi-component biobehavioral intervention

Also known as: psychosocial assessment, psychosocial assessment/care, psychosocial care, psychosocial care/assessment, psychosocial studies
Supportive care (psychosocial intervention)

Participate in multi-component biobehavioral intervention

Also known as: Behavior Conditioning Therapy, Behavior Therapy, Behavioral Modification, Behavioral Therapy, Behavioral Treatment
Supportive care (psychosocial intervention)

A multi-component intervention based on cognitive and behavioral principles will be used. It combines effective intervention strategies selected for their relevance to patients with recurrent cancer.

Supportive care (psychosocial intervention)

Participate in multi-component biobehavioral intervention

Also known as: intervention, educational
Supportive care (psychosocial intervention)

Eligibility Criteria

Age21 Years - 85 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosis of recurrent breast or gynecologic cancer (any site) with any disease-free interval; second primary cancers do not meet this criterion
  • English speaking
  • Able and willing to give informed consent
  • To be considered for the blood and saliva collection, women must fulfill the following secondary criteria:
  • Diagnosis of recurrent breast or ovarian cancer with any disease-free interval

You may not qualify if:

  • Residence \> 70 miles from research site
  • Subnormal intellectual potential (diagnosis of mental retardation)
  • Progressive neurological or chronic, progressive, debilitating condition (e.g., dementia)
  • Non-ambulatory
  • Life expectancy less than 160 days, per the treating oncologist
  • Current suicide risk sufficient to preclude treatment on an outpatient basis
  • Chronic inflammatory or autoimmune disorder (e.g., rheumatoid arthritis, lupus)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ohio State University Medical Center

Columbus, Ohio, 43210, United States

Location

Related Links

MeSH Terms

Conditions

Anxiety DisordersDepressionFatigueLeydig Cell TumorPainPeritoneal NeoplasmsPseudomyxoma PeritoneiBreast NeoplasmsUterine Cervical NeoplasmsEndometrial NeoplasmsFallopian Tube NeoplasmsGestational Trophoblastic DiseaseCarcinoma, Ovarian EpithelialVaginal NeoplasmsVulvar Neoplasms

Interventions

Psychiatric RehabilitationBehavior TherapyEarly Intervention, EducationalMethods

Condition Hierarchy (Ancestors)

Mental DisordersBehavioral SymptomsBehaviorSigns and SymptomsPathological Conditions, Signs and SymptomsSertoli-Leydig Cell TumorSex Cord-Gonadal Stromal TumorsNeoplasms, Gonadal TissueNeoplasms by Histologic TypeNeoplasmsTesticular NeoplasmsEndocrine Gland NeoplasmsNeoplasms by SiteGenital Neoplasms, MaleUrogenital NeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesMale Urogenital DiseasesEndocrine System DiseasesTesticular DiseasesGonadal DisordersNeurologic ManifestationsAbdominal NeoplasmsDigestive System NeoplasmsDigestive System DiseasesPeritoneal DiseasesAdenocarcinoma, MucinousAdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms, Cystic, Mucinous, and SerousBreast DiseasesSkin DiseasesSkin and Connective Tissue DiseasesUterine NeoplasmsGenital Neoplasms, FemaleUterine Cervical DiseasesUterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsFallopian Tube DiseasesAdnexal DiseasesTrophoblastic NeoplasmsNeoplasms, Germ Cell and EmbryonalPregnancy Complications, NeoplasticPregnancy ComplicationsOvarian NeoplasmsOvarian DiseasesVaginal DiseasesVulvar Diseases

Intervention Hierarchy (Ancestors)

RehabilitationTherapeuticsHealth ServicesHealth Care Facilities Workforce and ServicesPsychotherapyBehavioral Disciplines and ActivitiesChild Health ServicesCommunity Health ServicesPreventive Health ServicesInvestigative Techniques

Study Officials

  • Barbara Andersen, PhD

    Ohio State University Comprehensive Cancer Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

January 8, 2013

First Posted

January 10, 2013

Study Start

October 1, 2010

Primary Completion

January 1, 2012

Study Completion

January 1, 2012

Last Updated

October 9, 2015

Record last verified: 2015-10

Locations